Donepezil in the treatment of patients with Alzheimer’s disease

References

• Bowen DM, Smith CB, White P, Davison AN. Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain99(3), 459–496 (1976).
   PubMed Web of Science ®Google Scholar
• Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet2(8000), 1403 (1976).
   PubMed Web of Science ®Google Scholar
• Perry EK, Gibson PH, Blessed G, Perry RH, Tomlinson BE. Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue. J. Neurol. Sci.34(2), 247–265 (1977).
   PubMed Web of Science ®Google Scholar
• Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR. Alzheimer’s disease and senile dementia: loss of neurons in the basal forebrain. Science215(4537), 1237–1239 (1982).
   PubMed Web of Science ®Google Scholar
• Fink DM, Bores GM, Effland RC et al. Synthesis and evaluation of 5-amino-5,6,7,8-tetrahydroquinolinones as potential agents for the treatment of Alzheimer’s disease. J. Med. Chem.38(18), 3645–3651 (1995).
   PubMed Web of Science ®Google Scholar
• Sugimoto H, Tsuchiya Y, Sugumi H et al. Synthesis and structure–activity relationships of acetylcholinesterase inhibitors: 1-benzyl-4-(2-phthalimidoethyl)piperidine and related derivatives. J. Med. Chem.35(24), 4542–4548 (1992).
   PubMed Web of Science ®Google Scholar
• Thomsen T, Kewitz H. Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo. Life Sci.46(21), 1553–1558 (1990).
   PubMed Web of Science ®Google Scholar
• Tiseo PJ, Foley K, Friedhoff LT. An evaluation of the pharmacokinetics of donepezil HCl in patients with moderately to severely impaired renal function. Br. J. Clin. Pharmacol.46(Suppl. 1), 56–60 (1998).
   PubMed Web of Science ®Google Scholar
• Tiseo PJ, Foley K, Friedhoff LT. The effect of multiple doses of donepezil HCl on the pharmacokinetic and pharmacodynamic profile of warfarin. Br. J. Clin. Pharmacol.46(Suppl. 1), 45–50 (1998).
   PubMed Web of Science ®Google Scholar
• Tiseo PJ, Foley K, Friedhoff LT. Concurrent administration of donepezil HCl and theophylline: assessment of pharmacokinetic changes following multiple-dose administration in healthy volunteers. Br. J. Clin. Pharmacol.46(Suppl. 1), 35–39 (1998).
   PubMed Web of Science ®Google Scholar
• Tiseo PJ, Perdomo CA, Friedhoff LT. Concurrent administration of donepezil HCl and digoxin: assessment of pharmacokinetic changes. Br. J. Clin. Pharmacol.46(Suppl. 1), 40–44 (1998).
   PubMed Web of Science ®Google Scholar
• Tiseo PJ, Perdomo CA, Friedhoff LT. Concurrent administration of donepezil HCl and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses. Br. J. Clin. Pharmacol.46(Suppl. 1), 30–34 (1998).
   PubMed Web of Science ®Google Scholar
• Tiseo PJ, Perdomo CA, Friedhoff LT. Concurrent administration of donepezil HCl and cimetidine: assessment of pharmacokinetic changes following single and multiple doses. Br. J. Clin. Pharmacol.46(Suppl. 1), 25–29 (1998).
   PubMed Web of Science ®Google Scholar
• Ohnishi A, Mihara M, Kamakura H et al. Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer’s disease, in healthy young and elderly subjects. J. Clin. Pharmacol.33(11), 1086–1091 (1993).
   PubMed Web of Science ®Google Scholar
• Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Donepezil Study Group. Neurology50(1), 136–145 (1998).
   PubMed Web of Science ®Google Scholar
• Burns A, Rossor M, Hecker J et al. The effects of donepezil in Alzheimer’s disease – results from a multinational trial. Dement. Geriatr. Cogn. Disord.10(3), 237–244 (1999).
   PubMed Web of Science ®Google Scholar
• Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease. Neurology57(4), 613–620 (2001).
   PubMed Web of Science ®Google Scholar
• Mohs RC, Doody RS, Morris JC et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology57(3), 481–488 (2001).
   PubMed Web of Science ®Google Scholar
• Pratt RD, Perdomo CA, Surick IW, Ieni JR. Donepezil: tolerability and safety in Alzheimer’s disease. Int. J. Clin. Pract.56(9), 710–717 (2002).
   PubMed Web of Science ®Google Scholar
• Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch. Intern. Med.158(9), 1021–1031 (1998).
   PubMed Web of Science ®Google Scholar
• Winblad B, Engedal K, Soininen H et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology57(3), 489–495 (2001).
   PubMed Web of Science ®Google Scholar
• Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer’s disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. The Donepezil Study Group. Dementia7(6), 293–303 (1996).
   PubMedGoogle Scholar
• Gauthier S, Feldman H, Hecker J et al. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer’s disease. Int. Psychogeriatr.14(4), 389–404 (2002).
   PubMed Web of Science ®Google Scholar
• Geldmacher DS, Provenzano G, McRae T, Mastey V, Ieni JR. Donepezil is associated with delayed nursing home placement in patients with Alzheimer’s disease. J. Am. Geriatr. Soc.51(7), 937–944 (2003).
   PubMed Web of Science ®Google Scholar
• Feldman H, Gauthier S, Hecker J et al. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer’s disease and the effect on caregiver burden. J. Am. Geriatr. Soc.51(6), 737–744 (2003).
   PubMed Web of Science ®Google Scholar
• Wimo A, Winblad B, Shah SN, Chin W, Zhang R, McRae T. Impact of donepezil treatment for Alzheimer’s disease on caregiver time. Curr. Med. Res. Opin.20(8), 1221–1225 (2004).
   PubMed Web of Science ®Google Scholar
• Feldman H, Gauthier S, Hecker J et al. Efficacy and safety of donepezil in patients with more severe Alzheimer’s disease: a subgroup analysis from a randomized, placebo-controlled trial. Int. J. Geriatr. Psychiatry20(6), 559–569 (2005).
   PubMed Web of Science ®Google Scholar
• Homma A, Imai Y, Tago H et al. Donepezil treatment of patients with severe Alzheimer’s disease in a Japanese population: results from a 24-week, double-blind, placebo-controlled, randomized trial. Dement. Geriatr. Cogn. Disord.25(5), 399–407 (2008).
   PubMed Web of Science ®Google Scholar
• Winblad B, Kilander L, Eriksson S et al. Donepezil in patients with severe Alzheimer’s disease: double-blind, parallel-group, placebo-controlled study. Lancet367(9516), 1057–1065 (2006).
   PubMed Web of Science ®Google Scholar
• Black SE, Doody R, Li H et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology69(5), 459–469 (2007).
   PubMed Web of Science ®Google Scholar
• Seow D, Gauthier S. Pharmacotherapy of Alzheimer disease. Can. J. Psychiatry52(10), 620–629 (2007).
   PubMed Web of Science ®Google Scholar
• Ancoli-Israel S, Amatniek J, Ascher S, Sadik K, Ramaswamy K. Effects of galantamine versus donepezil on sleep in patients with mild to moderate Alzheimer disease and their caregivers: a double-blind, head-to-head, randomized pilot study. Alzheimer Dis. Assoc. Disord.19(4), 240–245 (2005).
   PubMed Web of Science ®Google Scholar
• Wilcock G, Howe I, Coles H et al. A long-term comparison of galantamine and donepezil in the treatment of Alzheimer’s disease. Drugs Aging20(10), 777–789 (2003).
   PubMed Web of Science ®Google Scholar
• Bullock R, Bergman H, Touchon J et al. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer’s disease. Curr. Med. Res. Opin22(3), 483–494 (2006).
   PubMed Web of Science ®Google Scholar
• Bullock R, Touchon J, Bergman H et al. Rivastigmine and donepezil treatment in moderate to moderately severe Alzheimer’s disease over a 2-year period. Curr. Med. Res. Opin.21(8), 1317–1327 (2005).
   PubMed Web of Science ®Google Scholar
• Winblad B, Cummings J, Andreasen N et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer’s disease – rivastigmine patch versus capsule. Int. J. Geriatr. Psychiatry22(5), 456–467 (2007).
   PubMed Web of Science ®Google Scholar
• Ellis JM. Cholinesterase inhibitors in the treatment of dementia. J. Am. Osteopath. Assoc.105(3), 145–158 (2005).
   PubMedGoogle Scholar
• Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst. Rev.1, CD001190 (2006).
   PubMedGoogle Scholar
• Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, van den Bussche H. Cholinesterase inhibitors for patients with Alzheimer’s disease: systematic review of randomised clinical trials. BMJ331(7512), 321–327 (2005).
   PubMed Web of Science ®Google Scholar
• Feldman H, Gauthier S, Hecker J et al. Economic evaluation of donepezil in moderate to severe Alzheimer disease. Neurology63(4), 644–650 (2004).
   PubMed Web of Science ®Google Scholar
• Courtney C, Farrell D, Gray R et al. Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind trial. Lancet363(9427), 2105–2115 (2004).
   PubMed Web of Science ®Google Scholar
• Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst. Rev.1, CD005593 (2006).
   PubMed Web of Science ®Google Scholar
• Bullock R, Dengiz A. Cognitive performance in patients with Alzheimer’s disease receiving cholinesterase inhibitors for up to 5 years. Int. J. Clin. Pract.59(7), 817–822 (2005).
   PubMed Web of Science ®Google Scholar
• Rogers SL, Doody RS, Pratt RD, Ieni JR. Long-term efficacy and safety of donepezil in the treatment of Alzheimer’s disease: final analysis of a US multicentre open-label study. Eur. Neuropsychopharmacol.10(3), 195–203 (2000).
   PubMed Web of Science ®Google Scholar
• Lopez OL, Becker JT, Saxton J, Sweet RA, Klunk W, DeKosky ST. Alteration of a clinically meaningful outcome in the natural history of Alzheimer’s disease by cholinesterase inhibition. J. Am. Geriatr. Soc.53(1), 83–87 (2005).
   PubMed Web of Science ®Google Scholar
• Cummings JL, McRae T, Zhang R. Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders. Am. J. Geriatr. Psychiatry14(7), 605–612 (2006).
   PubMed Web of Science ®Google Scholar
• Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA291(3), 317–324 (2004).
   PubMed Web of Science ®Google Scholar
• Orgogozo JM, Gilman S, Dartigues JF et al. Subacute meningoencephalitis in a subset of patients with AD after Ab42 immunization. Neurology61(1), 46–54 (2003).
   PubMed Web of Science ®Google Scholar
• Meguro M, Kasai M, Akanuma K, Ishii H, Yamaguchi S, Meguro K. Comprehensive approach of donepezil and psychosocial interventions on cognitive function and quality of life for Alzheimer’s disease: the Osaki-Tajiri Project. Age Ageing37(4), 469–473 (2008).
   PubMed Web of Science ®Google Scholar
• Mittelman MS, Brodaty H, Wallen AS, Burns A. A three-country randomized controlled trial of a psychosocial intervention for caregivers combined with pharmacological treatment for patients with Alzheimer disease: effects on caregiver depression. Am. J. Geriatr. Psychiatry16(11), 893–904 (2008).
   PubMed Web of Science ®Google Scholar
• Onder G, Zanetti O, Giacobini E et al. Reality orientation therapy combined with cholinesterase inhibitors in Alzheimer’s disease: randomised controlled trial. Br. J. Psychiatry187, 450–455 (2005).
   PubMed Web of Science ®Google Scholar